Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ6 | P48051 | 8/20 | 0.58 |
| ▸ | KCNJ5 | P48544 | 8/20 | 0.58 |
| ▸ | KCNJ3 | P48549 | 8/20 | 0.58 |
| ▸ | BRAF | P15056 | 12/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30486169 | 1.00 | KCNJ6 (0.58) | KCNJ6KCNJ5KCNJ3BRAF | |
| SCHEMBL25426339 | 0.86 | BRAF (0.58) | BRAF | |
| SCHEMBL30486127 | 0.86 | BRAF (0.58) | BRAF | |
| SCHEMBL30486143 | 0.85 | BRAF (0.73) | BRAF | |
| SCHEMBL25243132 | 0.85 | BRAF (0.73) | BRAF | |
| SCHEMBL25246469 | 0.84 | BRAF (0.55) | KCNJ6KCNJ5KCNJ3BRAF | |
| SCHEMBL30486131 | 0.84 | BRAF (0.55) | KCNJ6KCNJ5KCNJ3BRAF | |
| SCHEMBL25796308 | 0.84 | BRAF (0.52) | BRAF | |
| SCHEMBL28706549 | 0.84 | BRAF (0.74) | KCNJ6KCNJ5KCNJ3BRAF | |
| SCHEMBL25244685 | 0.77 | BRAF (0.74) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400551-A1 | NEK7 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2024-12-05 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | KCNJ6 2508/4885KCNJ5 2792/4885KCNJ3 2397/4885 |
| US-20240400551-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | KCNJ6 1695/4885KCNJ5 1680/4885KCNJ3 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.